ES2095938T3 - Procedimiento y composiciones para el tratamiento de lesiones. - Google Patents

Procedimiento y composiciones para el tratamiento de lesiones.

Info

Publication number
ES2095938T3
ES2095938T3 ES91909076T ES91909076T ES2095938T3 ES 2095938 T3 ES2095938 T3 ES 2095938T3 ES 91909076 T ES91909076 T ES 91909076T ES 91909076 T ES91909076 T ES 91909076T ES 2095938 T3 ES2095938 T3 ES 2095938T3
Authority
ES
Spain
Prior art keywords
injuries
compositions
procedure
treatment
chemotherapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91909076T
Other languages
English (en)
Inventor
David V Goeddel
Charles H Schmelzer
Grace H W Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27055814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2095938(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2095938T3 publication Critical patent/ES2095938T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5415—Leukaemia inhibitory factor [LIF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE UTILIZAN EL FACTOR D, LA HORMONA DEL CRECIMIENTO, EL IL-1 Y LOS FACTORES DE NECROSIS TUMORALES, SOLOS O EN COMBINACION, COMO AGENTES CITOPROTECTORES SINERGISTICOS PARA PACIENTES EXPUESTOS A DOSIS TOXICAS DE RADIACION IONIZANTE Y/O QUIMIOTERAPIA. SE SUMINISTRAN REGIMENES CITOPROTECTORES SINERGISTICOS QUE SON PARTICULARMENTE UTILES EN LA REDUCCION DE LA MORBIDIDAD Y DE LA MORTALIDAD EN TERAPIAS CONTRA EL CANCER. SE DESCRIBE EL USO DEL FACTOR D, DE LA HORMONA DEL CRECIMIENTO, DEL IL-1 Y DE LOS FACTORES DE NECROSIS TUMORALES, SOLOS O EN COMBINACION, PARA LA PREVENCION Y EL TRATAMIENTO DE LA ALOPECIA. SE PURIFICA EL FACTOR D MEDIANTE LA PRECIPITACION DE PROTEINAS CONTAMINANTES A UN PH MUY ACIDO Y SE ALMACENA DE FORMA ESTABLE A DICHO PH.
ES91909076T 1990-04-10 1991-04-09 Procedimiento y composiciones para el tratamiento de lesiones. Expired - Lifetime ES2095938T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50734190A 1990-04-10 1990-04-10
US60284990A 1990-10-26 1990-10-26

Publications (1)

Publication Number Publication Date
ES2095938T3 true ES2095938T3 (es) 1997-03-01

Family

ID=27055814

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91909076T Expired - Lifetime ES2095938T3 (es) 1990-04-10 1991-04-09 Procedimiento y composiciones para el tratamiento de lesiones.

Country Status (11)

Country Link
US (2) US5843422A (es)
EP (2) EP0731109A1 (es)
JP (1) JP3266248B2 (es)
AT (1) ATE144711T1 (es)
CA (1) CA2078544C (es)
DE (1) DE69122960T3 (es)
DK (1) DK0527852T3 (es)
ES (1) ES2095938T3 (es)
GR (1) GR3022097T3 (es)
IL (1) IL97779A (es)
WO (1) WO1991015227A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200176A (en) * 1989-10-06 1993-04-06 Genentech, Inc. Method for protection of ischemic tissues using tumor nerosis factor
US5370870A (en) * 1989-10-06 1994-12-06 Genentech, Inc. Method for protection against reactive oxygen species
IL97779A (en) * 1990-04-10 2000-01-31 Genentech Inc Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof
DK0554381T3 (da) * 1990-10-25 1996-04-09 Genentech Inc Anvendelse af beskyttende midler mod reaktive oxygenforbindelser
US5460810A (en) 1992-09-02 1995-10-24 Genetics Institute, Inc. Method for maintaining gut epithelial cells by treatment with a cytokine such as interleukin 11
US7602940B2 (en) 1998-04-16 2009-10-13 Digimarc Corporation Steganographic data hiding using a device clock
FR2786104B1 (fr) * 1998-11-25 2002-12-27 Centre Nat Rech Scient Inhibiteurs de l'activation de nf-kb, et leurs utilisations pharmaceutiques
US8288366B2 (en) 2006-06-20 2012-10-16 Chochinov Ronald H Formulation for hair growth
EA021042B1 (ru) * 2009-10-08 2015-03-31 Юнайтед Технолоджиес Ют Аг Способ снижения выпадения волос при помощи косметических композиций, содержащих интерлейкин-1 альфа
JP5913479B2 (ja) * 2014-08-11 2016-04-27 リゼロン、インク． ヒト成長ホルモンを有効成分として含む発毛の促進用の組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321832A (en) * 1980-03-07 1982-03-30 Rockwell International Corporation High accuracy measuring apparatus
NZ212207A (en) * 1984-05-31 1991-07-26 Genentech Inc Recombinant lymphotoxin
GR851626B (es) * 1984-07-05 1985-11-26 Genentech Inc
JPH01501862A (ja) * 1986-03-14 1989-06-29 シェリング・コ−ポレ−ション インタ−フェロン及び放射線療法による癌の治療
DE3613167A1 (de) † 1986-04-18 1987-10-29 Basf Ag Verwendung von tnf zur herstellung von arzneimitteln
IL80005A (en) * 1986-09-10 1992-11-15 Yeda Res & Dev Compositions for modulating the effect of tnf and il-1
US4985241A (en) * 1986-11-21 1991-01-15 Cetus Corporation Therapeutic combination of free-radical scavenger and tumor necrosis factor
PT87133B (pt) * 1987-04-02 1992-07-31 Amrad Corp Ltd Metodo de purificacao do factor inibidor da leucemia (lif) e de composicoes farmaceuticas contendo polipeptidos com actividade do lif
ZA893063B (en) * 1988-04-27 1990-01-31 Immunomedics Inc Improved radiotherapy
WO1990002183A1 (en) * 1988-08-18 1990-03-08 Genetics Institute, Inc. Production of a novel lymphokine exhibiting differentiation inhibitory activity
CA2048673A1 (en) * 1989-03-07 1990-09-08 Donald Metcalf Metabolic effects of leukaemia inhibitory factor on bone
US5370870A (en) * 1989-10-06 1994-12-06 Genentech, Inc. Method for protection against reactive oxygen species
IL97779A (en) * 1990-04-10 2000-01-31 Genentech Inc Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response

Also Published As

Publication number Publication date
DE69122960T3 (de) 2002-05-29
DK0527852T3 (es) 1997-02-17
EP0527852B2 (en) 2001-02-21
AU7856591A (en) 1991-10-30
US5725851A (en) 1998-03-10
GR3022097T3 (en) 1997-03-31
DE69122960D1 (de) 1996-12-05
WO1991015227A1 (en) 1991-10-17
EP0527852A1 (en) 1993-02-24
DE69122960T2 (de) 1997-04-03
IL97779A (en) 2000-01-31
IL97779A0 (en) 1992-06-21
ATE144711T1 (de) 1996-11-15
JPH05506663A (ja) 1993-09-30
US5843422A (en) 1998-12-01
EP0527852B1 (en) 1996-10-30
AU638839B2 (en) 1993-07-08
CA2078544A1 (en) 1991-10-11
CA2078544C (en) 2008-02-26
JP3266248B2 (ja) 2002-03-18
EP0731109A1 (en) 1996-09-11

Similar Documents

Publication Publication Date Title
DK108491D0 (da) Nucleosider og nucleosidanaloge samt farmaceutiske praeparater indeholdende disse forbindelser
TW229156B (es)
DK0582318T3 (da) Udnyttelse af de anticarcinogene og antivirale egenskaber hos carnosinsyre
ES2154686T3 (es) Compuestos de piridazino-quinolina.
ATE181329T1 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
MX9303124A (es) Compuestos organicos de benzodiazepina, procedimiento para su preparacion y formulaciones farmaceuticas que los contienen.
KR0141913B1 (en) Anti-virus agents
ES2095938T3 (es) Procedimiento y composiciones para el tratamiento de lesiones.
FI945975A0 (fi) Haarautuneella aminoryhmällä substituoituja tiatsoleja, menetelmiä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia
NZ212768A (en) 2-substituted-1,3-propylidene diphosphonate derivatives and pharmaceutical compositions
AU5670690A (en) Lysolecithin derivatives for treating autoimmune diseases
NO923199D0 (no) Terapeutiske forbindelser
BR9302197A (pt) Compostos fenilbenzamidas fungicidas,processo para suas preparacoes,composicao fungicida e processo para a protecao de plantas contra doencas fungicas
FI923664A0 (fi) Piperidinderivat.
ZA886097B (en) Pharmaceutical composition for the treatment of psoriasis
ATE113477T1 (de) Therapeutisch wirksames stoffgemisch aus glutathion- und anthocyan-verbindungen.
DK0610078T3 (da) Cytotoksisk og antiviral forbindelse.
ATE69238T1 (de) Monoalkylester-sulfate von glutathion und verfahren zu deren herstellung.
PT91153A (pt) Processo para a preparacao de um ester de 9-(2-hidroxi-etoxi-metil)guanina e de composicoes que contem
FI923662A0 (fi) Terapeutiska medel.
ATE101119T1 (de) Butensaeure-amide, deren salze, diese enthaltende pharmazeutische zusammensetzungen und verfahren zu deren herstellung.
DK656889A (da) Azabicykliske derivater
ATE109485T1 (de) Derivate von n-(vincristinyl-23) und n- (noranhydro-5-vinblastinyl-23) von amino-1- methylphosphonsäure, ihre verfahren zur herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ES8602019A1 (es) Un procedimiento para preparar compuestos de cefalosporina
ATE155470T1 (de) Cephem verbindungen mit antimicrobizide eigenschaften

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 527852

Country of ref document: ES